Low Grade Lymphoma Clinical Trial
Official title:
High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma
Verified date | August 2011 |
Source | AHS Cancer Control Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation.
Status | Completed |
Enrollment | 60 |
Est. completion date | June 2010 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - indolent histology lymphomas after relapse 1 or 2 LVEF > 50% Creatinine < 150 umol/L bilirubin < 30 umol/L wbc >3.5X10^9/L platelets >100X10^9/L other medical condition as controlled Exclusion Criteria: - pregnant lactating HIV positive CNS involvement by lymphoma other malignancy |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Tom Baker Cancer Centre | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
Alberta Health Services |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | feasibility | |||
Primary | mortality | |||
Primary | overall survival | |||
Primary | event free survival |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04773769 -
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
|
N/A | |
Completed |
NCT00791011 -
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
|
Phase 1 | |
Completed |
NCT01300026 -
AMG 319 Lymphoid Malignancy FIH
|
Phase 1 |